Marc Ribo is an interventional neurologist from Hospital Vall d'Hebron in Barcelona that underwent a vascular neurology fellowship at University of Texas-Houston (2004-5). His research work over the last 20 years was focused on improving access and efficacy of reperfusion treatments for acute stroke. He has a special interest in coordinating acute stroke management at the prehospital setting, integrating prehospital scales, telemedicine systems and artificial intelligence based solutions. He is the Co-Pi of the RACECAT study. He also has a special interest in improving in hospital workflows such as direct transfer to angio-suite (CO-PI of the ANGIOCAT and WE TRUST studies). He contributed to the growth of endovascular treatment of stroke exploring new selection protocols and novel devices. He is the Co-founder of Anaconda Biomed.